Skip to main content

Table 2 Association between MEG3 rs10132552 and clinic-pathological parameters of breast cancer patients

From: Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer

  rs10132552 n(%) P value
TT TC CC Dominant Recessive co-dominant Additive
T stage
 1~2 34(44.7) 27(47.4) 7(87.5) 0.37 0.022* 0.867 0.07
 3~4 42(55.3) 30(52.6) 1(12.5)
Lymph node status
 Negative 8(11) 10(18.2) 2(25) 0.184 0.397 0.346 0.364
 Positive 65(89) 45(81.8) 6(75)
ER
 Negative 22(28.2) 18(31) 2(25) 0.783 0.79 0.686 0.905
 Positive 56(71.8) 40(69) 6(75)
PR
 Negative 15(19.2) 14(24.1) 1(12.5) 0.607 0.55 0.423 0.656
 Positive 63(80.8) 44(75.9) 7(87.5)
HER2
 Negative 54(69.2) 34(58.6) 4(50) 0.147 0.4 0.28 0.312
 Positive 24(30.8) 24(41.4) 4(50)
Ki67
 Low expression 21(28.4) 8(14.8) 4(50) 0.221 0.08 0.037* 0.045*
 High expression 53(71.6) 46(85.2) 4(50)
Menopausal status
 Premenopausal 35(44.9) 25(43.1) 2(25) 0.632 0.289 0.992 0.557
 Postmenopausal 43(55.1) 33(56.9) 6(75)
  1. Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor − 2
  2. *P < 0.05